In patients treated with ICB, high CXCL13 expression leads to more favorable tumor outcomes perhaps due to CXCR5+CD8 T cells expanding the effector T cell pool or as a consequence of these cells increasing proliferation while resisting apoptosis (11, 82). This evidence concerns the gene CXCL13 and neoplasm.